Department of Pediatrics, Peking University First Hospital, Beijing, 100034, China.
World J Pediatr. 2009 Nov;5(4):308-11. doi: 10.1007/s12519-009-0059-5. Epub 2009 Nov 13.
Proteinuria is one of the risk factors for the progression of renal diseases including Alport syndrome (AS), a hereditary glomerular renal disease. This study aimed to evaluate the efficacy of angiotensin converting enzyme inhibitors (ACEIs) and/or tripterygium, a Chinese herbal medicine widely used in Chinese patients with hematuria and proteinuria, on proteinuria in patients with AS.
Twenty-nine children were enrolled into this retrospective study. Patients were divided into 3 therapy groups: ACEI group, tripterygium group, and ACEI plus tripterygium group.
In the 29 children, 23 were male and 6 female. In the ACEI group and the tripterygium group, the effective rate was 87.5% and 25.0%, respectively and in the ACEI plus tripterygium group was 42.9%.
ACEI is effective in controlling proteinuria of AS patients. Tripterygium should be carefully administered in controlling proteinuria of AS patients.
蛋白尿是包括 Alport 综合征（AS）在内的多种肾脏疾病进展的风险因素之一，AS 是一种遗传性肾小球肾病。本研究旨在评估血管紧张素转换酶抑制剂（ACEI）和/或雷公藤（一种在中国广泛用于血尿和蛋白尿患者的中药）对 AS 患者蛋白尿的疗效。
本回顾性研究纳入了 29 名儿童。患者被分为 3 个治疗组：ACEI 组、雷公藤组和 ACEI 加雷公藤组。
在 29 名儿童中，男性 23 名，女性 6 名。在 ACEI 组和雷公藤组中，有效率分别为 87.5%和 25.0%，而在 ACEI 加雷公藤组中为 42.9%。
ACEI 可有效控制 AS 患者的蛋白尿。雷公藤在控制 AS 患者蛋白尿方面应谨慎使用。
